1. Complete Response (CR): disappearance of all target lesions 2. Partial Response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions 3. Stable Disease (SD): no significant change in tumor size 4. Progressive Disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of new lesions
RECIST has become widely adopted as the standard criteria for tumor response evaluation in clinical trials for a variety of solid tumors. Following the RECIST guidelines in cancer research and treatment allows for consistency in data analysis and interpretation, thus helping healthcare providers make more informed decisions regarding cancer treatment.
RECIST
Health Care Term
1. Complete Response (CR): disappearance of all target lesions 2. Partial Response (PR): at least a 30% decrease in the sum of the longest diameter of target lesions 3. Stable Disease (SD): no significant change in tumor size 4. Progressive Disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of new lesions
RECIST has become widely adopted as the standard criteria for tumor response evaluation in clinical trials for a variety of solid tumors. Following the RECIST guidelines in cancer research and treatment allows for consistency in data analysis and interpretation, thus helping healthcare providers make more informed decisions regarding cancer treatment.